Aarti Drugs Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Aarti Drugs wird ein Gewinn- und Umsatzwachstum von 36.4% bzw. 14.7% pro Jahr prognostiziert, während der Gewinn pro Aktie um 46.2% pro Jahr wachsen soll.
Wichtige Informationen
36.4%
Wachstumsrate der Gewinne
46.2%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 18.1% |
| Wachstumsrate der Einnahmen | 14.7% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 30 Jul 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
Sep 20
Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet
Sep 05Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?
May 04Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models
Feb 01Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00
Jan 30Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think
May 17These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well
Nov 22We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet
Aug 28Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching
Aug 19Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value
May 17Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock
Apr 04Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?
Mar 17Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 02What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?
Feb 17Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio
Feb 04
What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?
Jan 22Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth
Jan 07If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late
Dec 23Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly
Dec 08Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 23How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?
Nov 08Here's What We Learned About The CEO Pay At Aarti Drugs Limited (NSE:AARTIDRUGS)
Oct 11Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 514% Share Price Increase Shows How Capitalism Can Build Wealth
Sep 23Aarti Drugs Limited's (NSE:AARTIDRUGS) Business Is Trailing The Market But Its Shares Aren't
Sep 10Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2026 | 31,313 | 2,990 | 1,181 | N/A | 1 |
| 3/31/2025 | 27,239 | 2,152 | 765 | N/A | 1 |
| 6/30/2024 | 24,228 | 1,568 | N/A | N/A | N/A |
| 3/31/2024 | 25,286 | 1,714 | 1,326 | 3,589 | N/A |
| 12/31/2023 | 26,510 | 1,802 | N/A | N/A | N/A |
| 9/30/2023 | 27,090 | 1,802 | 1,213 | 3,171 | N/A |
| 6/30/2023 | 27,552 | 1,794 | N/A | N/A | N/A |
| 3/31/2023 | 27,161 | 1,663 | -315 | 1,333 | N/A |
| 12/31/2022 | 26,679 | 1,656 | N/A | N/A | N/A |
| 9/30/2022 | 26,387 | 1,872 | -836 | 700 | N/A |
| 6/30/2022 | 25,306 | 1,910 | N/A | N/A | N/A |
| 3/31/2022 | 24,886 | 2,050 | -816 | 704 | N/A |
| 12/31/2021 | 22,961 | 2,014 | N/A | N/A | N/A |
| 9/30/2021 | 21,916 | 2,111 | 137 | 1,322 | N/A |
| 6/30/2021 | 21,901 | 2,438 | N/A | N/A | N/A |
| 3/31/2021 | 21,548 | 2,804 | 667 | 1,550 | N/A |
| 12/31/2020 | 21,027 | 2,876 | N/A | N/A | N/A |
| 9/30/2020 | 20,459 | 2,474 | 1,338 | 2,070 | N/A |
| 6/30/2020 | 19,453 | 2,044 | N/A | N/A | N/A |
| 3/31/2020 | 18,061 | 1,414 | 2,028 | 2,507 | N/A |
| 12/31/2019 | 18,156 | 1,100 | N/A | N/A | N/A |
| 9/30/2019 | 17,222 | 1,031 | N/A | N/A | N/A |
| 6/30/2019 | 15,921 | 888 | N/A | N/A | N/A |
| 3/31/2019 | 15,609 | 898 | 688 | 1,431 | N/A |
| 12/31/2018 | 14,136 | 863 | N/A | N/A | N/A |
| 9/30/2018 | 13,689 | 887 | N/A | N/A | N/A |
| 6/30/2018 | 13,407 | 943 | N/A | N/A | N/A |
| 3/31/2018 | 12,436 | 823 | N/A | 698 | N/A |
| 12/31/2017 | 11,592 | 790 | N/A | N/A | N/A |
| 9/30/2017 | 11,340 | 735 | N/A | N/A | N/A |
| 6/30/2017 | 11,569 | 721 | N/A | N/A | N/A |
| 3/31/2017 | 11,952 | 818 | N/A | 1,748 | N/A |
| 12/31/2016 | 12,102 | 785 | N/A | N/A | N/A |
| 9/30/2016 | 11,856 | 776 | N/A | N/A | N/A |
| 6/30/2016 | 11,431 | 713 | N/A | N/A | N/A |
| 3/31/2016 | 11,349 | 687 | N/A | 1,333 | N/A |
| 12/31/2015 | 11,101 | 686 | N/A | N/A | N/A |
| 9/30/2015 | 11,047 | 744 | N/A | N/A | N/A |
| 6/30/2015 | 11,180 | 774 | N/A | N/A | N/A |
| 3/31/2015 | 10,943 | 773 | N/A | 1,046 | N/A |
| 12/31/2014 | 10,868 | 807 | N/A | N/A | N/A |
| 9/30/2014 | 10,490 | 721 | N/A | N/A | N/A |
| 6/30/2014 | 10,109 | 662 | N/A | N/A | N/A |
| 3/31/2014 | 9,699 | 608 | N/A | 954 | N/A |
| 12/31/2013 | 9,083 | 526 | N/A | N/A | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: AARTIDRUGSDas prognostizierte Gewinnwachstum (27.7% pro Jahr) liegt über der Sparquote (6.7%).
Ertrag vs. Markt: AARTIDRUGSDie Erträge des Unternehmens (27.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (16% pro Jahr).
Hohe Wachstumserträge: AARTIDRUGSEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: AARTIDRUGSDie Einnahmen des Unternehmens (11.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (9.4% pro Jahr).
Hohe Wachstumseinnahmen: AARTIDRUGSDie Einnahmen des Unternehmens (11.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von AARTIDRUGS in 3 Jahren voraussichtlich hoch sein wird